Universidade do Sul de Santa Catarina, Programa de Pós-Graduação em Ciências da Saúde, Tubarão, SC, Brasil.
Universidade do Sul de Santa Catarina, Faculdade de Medicina, Tubarão, SC, Brasil.
Rev Soc Bras Med Trop. 2021 Nov 12;54:e0385. doi: 10.1590/0037-8682-0385-2021. eCollection 2021.
The use of coronavirus disease 2019 RNA vaccines in pregnant women led to reports on the first cases of newborns with antibodies to sudden acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a phenomenon that was unknown when using immunizations with inactivated viruses. Thus, this study aimed to report a case of passive anti-SARS-CoV-2 immunity in a newborn through immunoprophylaxis of a pregnant woman who received the CoronaVac® vaccine in the third trimester of pregnancy. Twenty-four hours after delivery, samples were collected from the newborn and screened by enzyme immunoassays, which revealed antibodies to SARS-CoV-2.
使用 2019 年冠状病毒病 RNA 疫苗在孕妇中导致了首例新生儿对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)产生抗体的报告,这是在使用灭活病毒免疫时未知的现象。因此,本研究旨在报告一例通过在妊娠晚期接受科兴疫苗(CoronaVac®)免疫的孕妇进行免疫预防,新生儿获得被动 SARS-CoV-2 免疫力的病例。分娩后 24 小时,从新生儿采集样本并通过酶免疫分析法进行筛查,显示出对 SARS-CoV-2 的抗体。